Abstract
Hemophilia A and B—lack of factors VIII and IX, respectively—are the most common forms of hemophilia. This chapter reviews the pathogenesis of hemophilia, diagnosis, and treatment including the use of desmopressin and factor concentrates.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Croteau SE. Evolving complexity in hemophilia management. Pediatr Clin N Am. 2018;65(3):407–25.
Dunn A. The long and short of it: using the new factor products. Hematology Am Soc Hematol Educ Program. 2015;2015:26–32.
Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811–22.
Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood. 2019;133(5):399–406.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389–98.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
DeLoughery, T.G. (2019). Hemophilia. In: DeLoughery, T. (eds) Hemostasis and Thrombosis. Springer, Cham. https://doi.org/10.1007/978-3-030-19330-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-19330-0_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19329-4
Online ISBN: 978-3-030-19330-0
eBook Packages: MedicineMedicine (R0)